Moderna, Inc.

NasdaqGS:MRNA 주식 보고서

시가총액: US$24.6b

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Moderna 관리

관리 기준 확인 3/4

Moderna's CEO는 Stephane Bancel, Oct2011 에 임명되었습니다 의 임기는 12.83 년입니다. 총 연간 보상은 $ 17.07M, 9.2% 로 구성됩니다. 9.2% 급여 및 90.8% 보너스(회사 주식 및 옵션 포함). 는 $ 1.83B 가치에 해당하는 회사 주식의 5.49% 직접 소유합니다. 1.83B. 경영진과 이사회의 평균 재임 기간은 각각 4.3 년과 10.3 년입니다.

주요 정보

Stephane Bancel

최고 경영자

US$17.1m

총 보상

CEO 급여 비율9.2%
CEO 임기12.9yrs
CEO 소유권5.5%
경영진 평균 재임 기간4.4yrs
이사회 평균 재임 기간10.3yrs

최근 관리 업데이트

We Discuss Why Moderna, Inc.'s (NASDAQ:MRNA) CEO Compensation May Be Closely Reviewed

Apr 30
We Discuss Why Moderna, Inc.'s (NASDAQ:MRNA) CEO Compensation May Be Closely Reviewed

Recent updates

Moderna: Still Bullish View

Sep 20

Moderna: Fresh Sell-Off On Cost Cutting Initiatives, Short-Term Outlook Troubling

Sep 12

Moderna's Vaccine Progress Undermined By RSV Market Contraction (Rating Downgrade)

Aug 26

Lacklustre Performance Is Driving Moderna, Inc.'s (NASDAQ:MRNA) 28% Price Drop

Aug 18
Lacklustre Performance Is Driving Moderna, Inc.'s (NASDAQ:MRNA) 28% Price Drop

Analysts Have Lowered Expectations For Moderna, Inc. (NASDAQ:MRNA) After Its Latest Results

Aug 03
Analysts Have Lowered Expectations For Moderna, Inc. (NASDAQ:MRNA) After Its Latest Results

Moderna: State Of Play Ahead Of Q2 Earnings, I'm (Temporarily) Pessimistic

Jul 30

Moderna: Really Strong Competition

Jun 30

Moment Of Truth Approaches For Moderna's RSV Vaccine

Jun 18

What Moderna, Inc.'s (NASDAQ:MRNA) 27% Share Price Gain Is Not Telling You

Jun 06
What Moderna, Inc.'s (NASDAQ:MRNA) 27% Share Price Gain Is Not Telling You

Moderna: Betting On Bird Flu Rally Is A Poor Strategy For A Value Investor

May 23

Moderna Q1: A Promising Pipeline Is Undervalued

May 15

We Discuss Why Moderna, Inc.'s (NASDAQ:MRNA) CEO Compensation May Be Closely Reviewed

Apr 30
We Discuss Why Moderna, Inc.'s (NASDAQ:MRNA) CEO Compensation May Be Closely Reviewed

Moderna, Inc.'s (NASDAQ:MRNA) Prospects Need A Boost To Lift Shares

Apr 22
Moderna, Inc.'s (NASDAQ:MRNA) Prospects Need A Boost To Lift Shares

Moderna: Considering The Cancer Vaccine Angle

Apr 11

Moderna Continues To Build A Pipeline

Apr 03

Lukewarm Reaction To Moderna's Vaccine Day Sums Up Fine Margins In Play

Mar 27

Moderna, Inc. (NASDAQ:MRNA) Just Released Its Yearly Results And Analysts Are Updating Their Estimates

Feb 27
Moderna, Inc. (NASDAQ:MRNA) Just Released Its Yearly Results And Analysts Are Updating Their Estimates

Moderna: Counting On Pipeline Too Much

Feb 23

Moderna: Highly Uncertain Future For mRNA Vaccine In A Post-Pandemic World

Feb 16

Moderna: Fade 2025 Outlook

Jan 15

Moderna, Inc. (NASDAQ:MRNA) Held Back By Insufficient Growth Even After Shares Climb 26%

Dec 29
Moderna, Inc. (NASDAQ:MRNA) Held Back By Insufficient Growth Even After Shares Climb 26%

CEO 보상 분석

Stephane Bancel 의 보수는 Moderna 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Jun 30 2024n/an/a

-US$6b

Mar 31 2024n/an/a

-US$6b

Dec 31 2023US$17mUS$2m

-US$5b

Sep 30 2023n/an/a

-US$3b

Jun 30 2023n/an/a

US$1b

Mar 31 2023n/an/a

US$5b

Dec 31 2022US$19mUS$1m

US$8b

Sep 30 2022n/an/a

US$12b

Jun 30 2022n/an/a

US$14b

Mar 31 2022n/an/a

US$15b

Dec 31 2021US$18mUS$990k

US$12b

Sep 30 2021n/an/a

US$7b

Jun 30 2021n/an/a

US$3b

Mar 31 2021n/an/a

US$598m

Dec 31 2020US$13mUS$946k

-US$747m

Sep 30 2020n/an/a

-US$597m

Jun 30 2020n/an/a

-US$488m

Mar 31 2020n/an/a

-US$505m

Dec 31 2019US$9mUS$921k

-US$514m

Sep 30 2019n/an/a

-US$535m

Jun 30 2019n/an/a

-US$499m

Mar 31 2019n/an/a

-US$459m

Dec 31 2018US$59mUS$863k

-US$402m

Sep 30 2018n/an/a

-US$299m

Jun 30 2018n/an/a

-US$280m

Mar 31 2018n/an/a

-US$266m

Dec 31 2017US$7mUS$651k

-US$270m

보상 대 시장: Stephane 의 총 보상 ($USD 17.07M )은 US 시장( $USD 13.05M ).

보상과 수익: Stephane 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Stephane Bancel (51 yo)

12.9yrs

테뉴어

US$17,068,514

보상

Mr. Stephane Bancel serves as Board Director of Indigo Agriculture Inc since 2020. Mr Bancel serves as Interim President of Valera LLC. Mr. Bancel serves as a Special Partner at Flagship Pioneering since F...

리더십 팀

이름위치테뉴어보상소유권
Stephane Bancel
CEO & Director12.9yrsUS$17.07m5.49%
$ 1.3b
Stephen Hoge
Presidentno dataUS$7.34m0.42%
$ 102.2m
James Mock
Chief Financial Officer2yrsUS$4.32m0.0023%
$ 560.3k
Shannon Klinger
Chief Legal Officer & Corporate Secretary3.3yrsUS$4.31m0.0047%
$ 1.2m
Jerh Collins
Chief Technical Operations & Quality Officer1.7yrs데이터 없음데이터 없음
Brad Miller
Chief Information Officer1.7yrs데이터 없음데이터 없음
Lavina Talukdar
Senior VP & Head of Investor Relations5.4yrs데이터 없음데이터 없음
Colleen Hussey
Senior Director of Corporate Communicationsno data데이터 없음데이터 없음
Tracey Franklin
Chief Human Resources Officer4.9yrs데이터 없음데이터 없음
Melanie Ivarsson
Chief Development Officer4.7yrs데이터 없음데이터 없음
Dave Johnson
Chief Data & AI Officerno data데이터 없음데이터 없음
Charbel Haber
Senior VP & Head of Global Regulatory Science4.4yrs데이터 없음데이터 없음

4.4yrs

평균 재임 기간

50yo

평균 연령

경험이 풍부한 관리: MRNA 의 관리팀은 경험 ( 4.3 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름위치테뉴어보상소유권
Stephane Bancel
CEO & Director13.5yrsUS$17.07m5.49%
$ 1.3b
Noubar Afeyan
Co-Founder14.7yrsUS$663.52k0.58%
$ 142.2m
Elizabeth Tallett
Independent Director4.2yrsUS$481.27k0.00018%
$ 44.2k
Robert Langer
Member of Scientific Advisory Boardno dataUS$461.27k2.99%
$ 735.8m
Scott Canute
Member of Technology Advisory Board10.3yrs데이터 없음데이터 없음
Elizabeth Nabel
Independent Director3.5yrsUS$476.25k0.00055%
$ 135.2k
Fred Regnier
Member of Technology Advisory Board10.3yrs데이터 없음데이터 없음
Francois Nader
Independent Non Executive Director4.8yrsUS$481.27k0.0054%
$ 1.3m
James Swartz
Member of Technology Advisory Board10.3yrs데이터 없음데이터 없음
Ulrich von Andrian-Werburg
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Jack Szostak
Chairman of Scientific Advisory Board10.3yrs데이터 없음데이터 없음
John Aunins
Member of Technology Advisory Board10.3yrs데이터 없음데이터 없음

10.3yrs

평균 재임 기간

65yo

평균 연령

경험이 풍부한 이사회: MRNA 의 이사회는 노련하고 경험이 있습니다(평균 재직 기간 10.3 년).